TY - JOUR
T1 - Intermittent-hypoxia induced autophagy attenuates contractile dysfunction and myocardial injury in rat heart
AU - Maeda, Hideyuki
AU - Nagai, Hisashi
AU - Takemura, Genzou
AU - Shintani-Ishida, Kaori
AU - Komatsu, Masaaki
AU - Ogura, Sayoko
AU - Aki, Toshihiko
AU - Shirai, Mikiayasu
AU - Kuwahira, Ichiro
AU - Yoshida, Ken ichi
N1 - Funding Information:
This study was supported by a Grant-in-aid from the Ministry of Education, Culture, and Sports in Japan .
PY - 2013
Y1 - 2013
N2 - Sleep apnea syndrome (SAS) is considered to be associated with heart failure (HF). It is known that autophagy is induced in various heart diseases thereby promotes survival, but its excess may be maladaptive. Intermittent hypoxia (IH) plays pivotal role in the pathogenesis of SAS. We aimed to clarify the relationships among IH, autophagy, and HF. Rats underwent IH at a rate of 20. cycles/h (nadir of 4% O2 to peak of 21% O2 with 0% CO2) or normal air breathing (control) for 8. h/d for 3. weeks. IH increased the cardiac LC3II/LC3I ratio. The IH induced upregulation of LC3II was attenuated by the administration of an inhibitor of autophagosome formation 3-methyladenine (3-MA), but enhanced by an inhibitor of autophagosome-lysosome fusion chloroquine (CQ), showing enhanced autophagic flux in IH hearts. Electron microscopy confirmed an increase in autophagosomes and lysosomes in IH. With 3-MA or CQ, IH induced progressive deterioration of fractional shortening (FS) on echocardiography over 3. weeks, although IH, 3-MA, or CQ alone had no effects. With CQ, IH for 4. weeks increased serum troponin T levels, reflecting necrosis. Western blotting analyses showed dephosphorylation of Akt and mammalian target of rapamycin (mTOR) at Akt (Ser2448, 2481) sites, suggesting the activation of autophagy via Akt inactivation. Conclusions. IH-mediated autophagy maintains contractile function, whereas when autophagy is inhibited, IH induces systolic dysfunction due to myocyte necrosis. General significance. This study highlighted the potential implications of autophagy in cardio-protection in early SAS patients without comorbidity, reproduced in normal rats by 3~4. weeks of IH.
AB - Sleep apnea syndrome (SAS) is considered to be associated with heart failure (HF). It is known that autophagy is induced in various heart diseases thereby promotes survival, but its excess may be maladaptive. Intermittent hypoxia (IH) plays pivotal role in the pathogenesis of SAS. We aimed to clarify the relationships among IH, autophagy, and HF. Rats underwent IH at a rate of 20. cycles/h (nadir of 4% O2 to peak of 21% O2 with 0% CO2) or normal air breathing (control) for 8. h/d for 3. weeks. IH increased the cardiac LC3II/LC3I ratio. The IH induced upregulation of LC3II was attenuated by the administration of an inhibitor of autophagosome formation 3-methyladenine (3-MA), but enhanced by an inhibitor of autophagosome-lysosome fusion chloroquine (CQ), showing enhanced autophagic flux in IH hearts. Electron microscopy confirmed an increase in autophagosomes and lysosomes in IH. With 3-MA or CQ, IH induced progressive deterioration of fractional shortening (FS) on echocardiography over 3. weeks, although IH, 3-MA, or CQ alone had no effects. With CQ, IH for 4. weeks increased serum troponin T levels, reflecting necrosis. Western blotting analyses showed dephosphorylation of Akt and mammalian target of rapamycin (mTOR) at Akt (Ser2448, 2481) sites, suggesting the activation of autophagy via Akt inactivation. Conclusions. IH-mediated autophagy maintains contractile function, whereas when autophagy is inhibited, IH induces systolic dysfunction due to myocyte necrosis. General significance. This study highlighted the potential implications of autophagy in cardio-protection in early SAS patients without comorbidity, reproduced in normal rats by 3~4. weeks of IH.
KW - Autophagy
KW - Heart failure
KW - Intermittent hypoxia
KW - Sleep apnea syndrome
UR - http://www.scopus.com/inward/record.url?scp=84877351286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877351286&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2013.02.014
DO - 10.1016/j.bbadis.2013.02.014
M3 - Article
C2 - 23499993
AN - SCOPUS:84877351286
SN - 0925-4439
VL - 1832
SP - 1159
EP - 1166
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 8
ER -